German
|
English
|
French
Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
-
February
-
March
-
April
-
May
-
June
-
July
- August - September - Oktober - November - December |
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020
-
2021
-
2022
-
2023
-
2024
-
2025
- 2026
August 2026 - 60 products
L
IP
CI
Febuxostat Spirig HC 80 mg
14
10.30
27.60
10 %
Coated tablets: Febuxostatum 80 mg
Spirig HealthCare AG
B / SL / SG
FB
G
L
IP
CI
V/S
Comirnaty XFG (30
Mikrogramm)
Injektionsdispersion in
einer Fertigspritze
68.36
89.90
10 %
Pfizer AG
B / SL
FB
G
L
IP
CI
V/S
Spikevax XFG (50
Microgramm)
Injektionsdispersion in
einer Fertigspritze
73.09
94.75
10 %
Moderna Switzerland
GmbH
B / SL
FB
G
IP
Ambelvist 0.1 mmol/ nl
7.5 ml
k.A.
Bayer (Schweiz) AG
B
FB
G
IP
Ambelvist 0.1 mmol/ nl
10 ml
k.A.
Bayer (Schweiz) AG
B
FB
G
IP
Ambelvist 0.1 mmol/ ml
30 ml
k.A.
Bayer (Schweiz) AG
B
FB
G
IP
Ambelvist 0.1 mmol/ ml
65 ml
k.A.
Bayer (Schweiz) AG
B
FB
G
IP
CI
V/S
Comirnaty XFG (30
Mikrogramm)
Injektionsdispersion in
einer Fertigspritze
10
k.A.
Pfizer AG
B
FB
G
IP
CI
V/S
Spikevax XFG (50
Microgramm)
Injektionsdispersion in
einer Fertigspritze
10
k.A.
Moderna Switzerland
GmbH
B
FB
G
IP
CI
Triofan Antitussif
Levodrop 6 mg/ml
150 ml
k.A.
Sirup: Levodropropizinum 6 mg/ml
VERFORA SA
D
FB
G
Levosimendan Ideogen 12,5
mg/5 ml
5 ml
k.A.
Concentrate for infusion: Levosimendanum 12.5mg / 5ml
Ideogen AG
A
FB
G
Levosimendan Ideogen 12,5
mg/5 ml
4 x 5 ml
k.A.
Concentrate for infusion: Levosimendanum 12.5mg / 5ml
Ideogen AG
A
FB
G
IP
CI
Febuxostat Spirig HC 80 mg
28
k.A.
Coated tablets: Febuxostatum 80 mg
Spirig HealthCare AG
B
FB
G
IP
CI
Febuxostat Spirig HC 80 mg
98
k.A.
Coated tablets: Febuxostatum 80 mg
Spirig HealthCare AG
B
FB
G
Betahistin Spirig HC 8 mg
50
k.A.
Tablets: Betahistini Dihydrochloridum 8 mg
Spirig HealthCare AG
B
FB
G
Betahistin Spirig HC 8 mg
100
k.A.
Tablets: Betahistini Dihydrochloridum 8 mg
Spirig HealthCare AG
B
FB
G
Betahistin Spirig HC 16 mg
50
k.A.
Tablets: Betahistini Dihydrochloridum 16 mg
Spirig HealthCare AG
B
FB
G
Betahistin Spirig HC 16 mg
100
k.A.
Tablets: Betahistini Dihydrochloridum 16 mg
Spirig HealthCare AG
B
FB
G
Betahistin Spirig HC 24 mg
50
k.A.
Tablets: Betahistini Dihydrochloridum 24 mg
Spirig HealthCare AG
B
FB
G
Betahistin Spirig HC 24 mg
100
k.A.
Tablets: Betahistini Dihydrochloridum 24 mg
Spirig HealthCare AG
B
FB
G
IP
Ambelvist 0.1 mmol/ nl
15 ml
k.A.
Bayer (Schweiz) AG
B
FB
G
V/S
mNEXSPIKE 0.05 mg/mL
k.A.
Moderna Switzerland
GmbH
B
FB
G
V/S
mNEXSPIKE 0.05 mg/mL
10
k.A.
Moderna Switzerland
GmbH
B
FB
G
PicoMag Leman
2
k.A.
Leman SKL SA
B
FB
G
PicoMag Leman
300
k.A.
Leman SKL SA
B
FB
G
Ahzantive 2 mg/0.05 ml
k.A.
Injection solution in prefilled syringe: Afliberceptum 2mg / 0.05ml
Medvisis Switzerland AG
B
FB
G
CalciVital D3 500 mg /
1000 I.E.
30
k.A.
Chewing tablets: 2 Active Agents
EffRx Pharmaceuticals SA
D
FB
G
CalciVital D3 500 mg /
1000 I.E.
90
k.A.
Chewing tablets: 2 Active Agents
EffRx Pharmaceuticals SA
D
FB
G
IP
CI
Tofacitinib-Mepha 5 mg
56
k.A.
Coated tablets: Tofacitinibum 5 mg
Mepha Pharma AG
B
FB
G
IP
CI
Tofacitinib-Mepha 5 mg
60
k.A.
Coated tablets: Tofacitinibum 5 mg
Mepha Pharma AG
B
FB
G
IP
CI
Tofacitinib-Mepha 5 mg
60
k.A.
Coated tablets: Tofacitinibum 5 mg
Mepha Pharma AG
B
FB
G
IP
CI
Tofacitinib-Mepha 10 mg
56
k.A.
Coated tablets: Tofacitinibum 10 mg
Mepha Pharma AG
B
FB
G
IP
CI
Tofacitinib-Mepha 10 mg
60
k.A.
Coated tablets: Tofacitinibum 10 mg
Mepha Pharma AG
B
FB
G
IP
CI
Tofacitinib-Mepha 10 mg
60
k.A.
Coated tablets: Tofacitinibum 10 mg
Mepha Pharma AG
B
FB
G
Ruxolitinib Devatis 5 mg
56
k.A.
Tablets: Ruxolitinibum 5 mg
Devatis AG
A
FB
G
Ruxolitinib Devatis 10 mg
56
k.A.
Tablets: Ruxolitinibum 10 mg
Devatis AG
A
FB
G
Ruxolitinib Devatis 15 mg
56
k.A.
Tablets: Ruxolitinibum 15 mg
Devatis AG
A
FB
G
Ruxolitinib Devatis 20 mg
56
k.A.
Tablets: Ruxolitinibum 20 mg
Devatis AG
A
FB
G
Vi-De 3 capsules 800 U.I.
90
k.A.
Soft capsules: Cholecalciferolum 800 UI
VERFORA SA
D
FB
G
Vi-De 3 capsules 5600
U.I.
10
k.A.
Soft capsules: Cholecalciferolum 5600 UI
VERFORA SA
B
FB
G
Vi-De 3 capsules 25000
U.I.
10
k.A.
Soft capsules: Cholecalciferolum 25000 UI
VERFORA SA
B
FB
G
Qtaxem 25 mg/ml
60 ml
k.A.
Suspension (oral): Quetiapinum 25 mg/ml
Exeltis Suisse SA
B
FB
G
Qtaxem 25 mg/ml
120 ml
k.A.
Suspension (oral): Quetiapinum 25 mg/ml
Exeltis Suisse SA
B
FB
G
Lanreotid Advanz Pharma 60 mg
k.A.
Depot-Injektionslösung in einer Fertigspritze: Lanreotidum 60mg / 0.5ml
Advanz Pharma
Specialty Medicine
Switzerland GmbH
A
FB
G
Lanreotid Advanz Pharma 90 mg
k.A.
Depot-Injektionslösung in einer Fertigspritze: Lanreotidum 90mg / 0.5ml
Advanz Pharma
Specialty Medicine
Switzerland GmbH
A
FB
G
Lanreotid Advanz Pharma 120 mg
k.A.
Depot-Injektionslösung in einer Fertigspritze: Lanreotidum 120mg / 0.5ml
Advanz Pharma
Specialty Medicine
Switzerland GmbH
A
FB
G
Wezenla 45 mg / 0.5 ml
k.A.
Injektionslösung im Fertigpen: Ustekinumabum 45mg / 0.5ml
Amgen Switzerland AG
B
FB
G
Wezenla 90 mg / 1.0 ml
k.A.
Injektionslösung im Fertigpen: Ustekinumabum 90 mg/ml
Amgen Switzerland AG
B
FB
G
Rezzayo 200 mg
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Rezafunginum 200 mg
Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch
A
FB
G
Alcacyl Ibu 400
10
k.A.
Pulver zur Herstellung einer Suspension zum Einnehmen: Ibuprofenum Lysinum 683.34 mg
Hänseler AG
D
FB
G
Galli Ad 0.74 – 3.70 GBq
k.A.
Radionuklidgenerator: 2 Active Agents
b.e.imaging.ag
A
FB
G
IP
CI
Azithrolag 250 mg
4
k.A.
compresse rivestite con film: Azithromycinum 250 mg
Lagap SA
A
FB
G
IP
CI
Azithrolag 250 mg
6
k.A.
compresse rivestite con film: Azithromycinum 250 mg
Lagap SA
A
FB
G
IP
Azithrolag 500 mg
3
k.A.
compresse rivestite con film: Azithromycinum 500 mg
Lagap SA
A
FB
G
IP
CI
Dapalag 5 mg
28
k.A.
compresse rivestite con film: Dapagliflozinum 5 mg
Lagap SA
B
FB
G
IP
CI
Dapalag 5 mg
98
k.A.
compresse rivestite con film: Dapagliflozinum 5 mg
Lagap SA
B
FB
G
IP
Dapalag 10 mg
28
k.A.
compresse rivestite con film: Dapagliflozinum 10 mg
Lagap SA
B
FB
G
IP
Dapalag 10 mg
98
k.A.
compresse rivestite con film: Dapagliflozinum 10 mg
Lagap SA
B
FB
G
Dexulac Leman 80 mg/g
7 ml
k.A.
vernis à ongle médicamenteux: Ciclopiroxum 80 mg/g
Leman SKL SA
B
FB
G
Dexulac Leman 80 mg/g
10 ml
k.A.
vernis à ongle médicamenteux: Ciclopiroxum 80 mg/g
Leman SKL SA
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home